Page 43 - Read Online
P. 43

Page 328                                Genvigir et al. J Transl Genet Genom 2020;4:320-55  I  http://dx.doi.org/10.20517/jtgg.2020.37

             Ref.   [47]         [48]           [33]    [45]         [43]    [39]             [46]



             Clinical outcomes  No association of UGT1A9  c.-2152C>T, c.-275T>A or  c.98T>C variants with AR   or adverse events  No association of UGT1A9  genotype was associated  c.-440C>T (or c.-331T>C)  variant with gastrointestinal   adverse events  -  -  UGT1A9 c.-331C allele   was associated with  adverse events (especially   leukopenia)  UGT1A9 c.-2152CT and/ or c.-275TA genotypes was  associated with increased  risk for AR, on tacrolimus   treatment  UGT1A9 c.-27









             Pharmacokinetics  Treatment with MMF   2g (n = 32) and   UGT1A9 c.-2152T and/  or c.-275A alleles were   associated with MPA   pharmacokinetics,   including lower AUC 0- 12 and 6-12 , at 7 days post-  transplantation   UGT1A9 -665CT   with higher MPA C/D   and c.-440/c.-331TT/  CC genotypes were   associated with higher   MPA exposure   (AUC 0-2, 0-4 and 0-12 )  No association of   UGT1A9 I399T>C   variant with MPA   pharmacokinetics  UGT1A9 c.-275T>A and/  o








            Immunosuppressive   regimen  MMF  Tacrolimus  Corticosteroids   One-year follow-up  MMF  Cyclosporine  Corticosteroid-free  At Month 6   MMF  Tacrolimus  Corticosteroids   At day 28  MMF  Tacrolimus  Corticosteroids   Five-year follow-up  MMF  Cyclosporine  Tacrolimus  Corticosteroids   MMF  Cyclosporine  Tacrolimus  Corticosteroids   One-year follow-up  MMF   EC-MPS  Tacrolimus











             Population   95 adult patients  (Belgium)  40 adult patients  (Italy)  80 adult patients (Japan)  100 adult patients  (Belgium)  38 pediatric patients   (USA)  338 adult patients   133 adult patients - for   PK profile n = 30 (Spain)









             Study design  Prospective  Mixed   Prospective  Prospective  Retrospective (Case-  Control)  Prospective, multicenter  (FDCC Study)  Mixed  (Case-control)







             Allele frequency  c.-2152T: 7%  c.-275A: 9%  c.98C: 2%  c.-2152T: 1%   -1887G: 13%  -665T: 4%  -440/-331 T/C: 41%  c.-275A: 5%  c.98C: 0%  I399C: 36%  -  c.-2152T: 9%  -331C: 28%  c.-275A: 11%  c.98C: 0%  c.-2152T: 5%  c.-275A: 6%  c.98C: 2%  I399T: 38%  -










             Variant                                          (UGT1A9*3, c.98T>C)
                 rs17868320  (c.-2152C>T)  rs6731242  (-1887T>G)  rs13418420  (-1818T>C)   rs10176426  (-665C>T)  rs2741045  (c.-440C>T)   rs2741046  (c.-331T>C)  rs6714486  (c.-275T>A)  rs3832043  (-118delT)   rs72551330  rs2741049  (I399 T>C)





             Gene   UGT1A9
   38   39   40   41   42   43   44   45   46   47   48